Dermata Therapeutics IncNASDAQ:DRMA
- LAST PRICE1.2500
- TODAY'S CHANGE (%)0.0319 (2.6188%)
- Bid / Lots1.2300/ 1
- Ask / Lots1.2700/ 1
- Open / Previous Close1.2000 / 1.2181
- Day Range
- 52 Week Range
- Volume38,903
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DRMA |
|---|---|---|
| 09:32 ET | 1358 | 1.2 |
| 09:37 ET | 434 | 1.23 |
| 09:39 ET | 3348 | 1.2 |
| 09:46 ET | 100 | 1.2001 |
| 09:53 ET | 200 | 1.2499 |
| 09:57 ET | 385 | 1.23 |
| 10:33 ET | 150 | 1.21 |
| 11:09 ET | 970 | 1.2384 |
| 11:34 ET | 1630 | 1.21 |
| 11:36 ET | 250 | 1.2299 |
| 11:39 ET | 500 | 1.215 |
| 12:32 ET | 5012 | 1.24 |
| 12:33 ET | 6074 | 1.27 |
| 12:35 ET | 607 | 1.27 |
| 12:42 ET | 1799 | 1.26 |
| 01:06 ET | 12300 | 1.28 |
| 01:27 ET | 582 | 1.27 |
| 01:47 ET | 400 | 1.2337 |
| 02:12 ET | 800 | 1.25 |
| 02:23 ET | 100 | 1.25 |
Oct 8, 2024
Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024, from 4:16PM ET on Tuesday Oct 08, 2024 by Dow Jones
4:16PM ET on Tuesday Oct 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Dermata Therapeutics Inc | 1.8M | -0.1x | --- |
Zyversa Therapeutics Inc | 1.9M | 0.0x | --- |
Panbela Therapeutics Inc | 1.8M | 0.0x | --- |
Kiromic Biopharma Inc | 1.7M | -0.1x | --- |
Pharmagreen Biotech Inc | 1.7M | -3.0x | --- |
Agentix Corp | 2.0M | -6.1x | --- |
Company Information
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, DMT310, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 50 million patients. Its second product candidate utilizing its Spongilla technology is DMT410, its combination treatment. DMT410 is intended to consist of one treatment of its proprietary sponge powder followed by one topical application of botulinum toxin for delivery into the dermis.
Contact Information
- Headquarters
- 3525 Del Mar Heights Rd., #322SAN DIEGO, CA, United States 92130
- Phone
- 858-223-0882
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer
- Gerald Proehl
- Chief Financial Officer, Senior Vice President
- Kyri Van Hoose
- Senior Vice President - Regulatory Affairs & Quality Assurance
- Maria Bedoya Toro Munera
- Senior Vice President, Chief Development Officer
- Christopher Nardo
- Lead Independent Director
- David Hale
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-19.42 |
Book Value | $24.25 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
